Menu
Back to User profile » Dr Haya Ascher-Svanum
Papers published by Dr Haya Ascher-Svanum:
The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy
Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H
ClinicoEconomics and Outcomes Research 2013, 5:407-418
Published Date: 14 August 2013
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR
Neuropsychiatric Disease and Treatment 2012, 8:259-266
Published Date: 18 June 2012
One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T
Pragmatic and Observational Research 2012, 3:41-49
Published Date: 14 June 2012
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
Ascher-Svanum H, Montgomery WS, McDonnell DP, Coleman KA, Feldman PD
International Journal of General Medicine 2012, 5:391-398
Published Date: 4 May 2012
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
Ascher-Svanum H, Brnabic AJM, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K
Neuropsychiatric Disease and Treatment 2012, 8:113-118
Published Date: 15 March 2012
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
Montgomery W, Treuer T, Karagianis J, Ascher-Svanum H, Harrison G
Patient Preference and Adherence 2012, 6:109-125
Published Date: 1 February 2012
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M
ClinicoEconomics and Outcomes Research 2012, 4:13-19
Published Date: 13 January 2012
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M
Patient Preference and Adherence 2011, 5:611-617
Published Date: 14 December 2011
Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence
Kelin K, Lambert TJR, Brnabic AJM, Newton R, Ye W, Escamilla RI, Chen KP, Don L, Montgomery W, Karagianis J, Ascher-Svanum H
Patient Preference and Adherence 2011, 5:213-222
Published Date: 9 May 2011
Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, Kane JM
ClinicoEconomics and Outcomes Research 2011, 3:79-87
Published Date: 20 April 2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries et al
ClinicoEconomics and Outcomes Research 2011, 3:9-14
Published Date: 11 January 2011
Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
Haya Ascher-Svanum, Baojin Zhu, Douglas E Faries, Jonathan P Lacro, Christian R Dolder, Xiaomei Peng
Patient Preference and Adherence 2008, 2:67-77
Published Date: 13 March 2008